GlassScriptPhysician profile
Mouhamad Bazzi
NPI 1265619878
$9,144.31
in general payments reported to CMS, 2019-2025
74 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,448 · 2020: $1,571 · 2021: $811 · 2022: $356 · 2023: $548 · 2024: $893 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919 · Education: $40.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.53 |
| Education | $40.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $913.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $793.06 | 2019-2025 | Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $650.07 | 2019-2025 | Opdivo, Eliquis |
| Genzyme Corporation | $519.24 | 2019-2025 | |
| Pfizer INC. | $512.89 | 2019-2025 | |
| Janssen Biotech, INC. | $431.65 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $342.02 | 2020-2025 | Ojjaara, Blenrep, Zejula |
| Amgen INC. | $320.71 | 2019-2022 | |
| Genentech USA, INC. | $308.90 | 2019-2025 | Polivy |
| Pharmacyclics LLC, An Abbvie Company | $287.61 | 2019-2023 | Imbruvica |
| Astellas Pharma US INC | $231.55 | 2019-2025 | Padcev |
| Janssen Pharmaceuticals, INC | $192.76 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $187.66 | 2019-2023 | Keytruda |
| Lilly USA, LLC | $167.96 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Celgene Corporation | $161.09 | 2019-2025 | Reblozyl |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mouhamad Bazzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.